Selected research
Market Structure
Global Immunology Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Immunology Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Immunology Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Immunology Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Immunology Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Immunology Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Immunology Drug include Eisai Co., Eli Lilly and Company, Pfizer, GlaxoSmithKline plc, Bayer AG, Seattle Genetics, Sanofi Aventis LLC., Genentech and F. Hoffmann-La Roche Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Immunology Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Immunology Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Immunology Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Immunology Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Immunology Drug Segment by Company
Eisai Co.
Eli Lilly and Company
Pfizer
GlaxoSmithKline plc
Bayer AG
Seattle Genetics
Sanofi Aventis LLC.
Genentech
F. Hoffmann-La Roche Ltd.
Autoimmune Inc.
Active Biotech
Abbott Laboratories
Immunology Drug Segment by Type
Monoclonal Antibodies (mAb)
Antibody Drug Conjugates
Immunosuppressive medication
Others
Immunology Drug Segment by Application
Cancer Research Centers and Institutes
Hospitals
Clinics
Immunology Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immunology Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Immunology Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immunology Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Immunology Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immunology Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Immunology Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Immunology Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal Antibodies (mAb)
- Antibody Drug Conjugates
- Immunosuppressive medication
- Others
Applications
- Cancer Research Centers and Institutes
- Hospitals
- Clinics
Companies covered
- Eisai Co.
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline plc
- Bayer AG
- Seattle Genetics
- Sanofi Aventis LLC.
- Genentech
- F. Hoffmann-La Roche Ltd.
- Autoimmune Inc.
- Active Biotech
- Abbott Laboratories
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Immunology Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Immunology Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Immunology Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Immunology Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Immunology Drug Market Dynamics
- 2.1 Immunology Drug Industry Trends
- 2.2 Immunology Drug Industry Drivers
- 2.3 Immunology Drug Industry Opportunities and Challenges
- 2.4 Immunology Drug Industry Restraints
3 Immunology Drug Market by Manufacturers
- 3.1 Global Immunology Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Immunology Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Immunology Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Immunology Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Immunology Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Immunology Drug Manufacturers, Product Type & Application
- 3.7 Global Immunology Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Immunology Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Immunology Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Immunology Drug Tier 1, Tier 2, and Tier 3
4 Immunology Drug Market by Type
- 4.1 Immunology Drug Type Introduction
- 4.1.1 Monoclonal Antibodies (mAb)
- 4.1.2 Antibody Drug Conjugates
- 4.1.3 Immunosuppressive medication
- 4.1.4 Others
- 4.2 Global Immunology Drug Sales by Type
- 4.2.1 Global Immunology Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Immunology Drug Sales by Type (2021-2032)
- 4.2.3 Global Immunology Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Immunology Drug Revenue by Type
- 4.3.1 Global Immunology Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Immunology Drug Revenue by Type (2021-2032)
- 4.3.3 Global Immunology Drug Revenue Market Share by Type (2021-2032)
5 Immunology Drug Market by Application
- 5.1 Immunology Drug Application Introduction
- 5.1.1 Cancer Research Centers and Institutes
- 5.1.2 Hospitals
- 5.1.3 Clinics
- 5.2 Global Immunology Drug Sales by Application
- 5.2.1 Global Immunology Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Immunology Drug Sales by Application (2021-2032)
- 5.2.3 Global Immunology Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Immunology Drug Revenue by Application
- 5.3.1 Global Immunology Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Immunology Drug Revenue by Application (2021-2032)
- 5.3.3 Global Immunology Drug Revenue Market Share by Application (2021-2032)
6 Global Immunology Drug Sales by Region
- 6.1 Global Immunology Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Immunology Drug Sales by Region (2021-2032)
- 6.2.1 Global Immunology Drug Sales by Region (2021-2026)
- 6.2.2 Global Immunology Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Immunology Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Immunology Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Immunology Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Immunology Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Immunology Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Immunology Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Immunology Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Immunology Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Immunology Drug Revenue by Region
- 7.1 Global Immunology Drug Revenue by Region
- 7.1.1 Global Immunology Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Immunology Drug Revenue by Region (2021-2026)
- 7.1.3 Global Immunology Drug Revenue by Region (2027-2032)
- 7.1.4 Global Immunology Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Immunology Drug Revenue (2021-2032)
- 7.2.2 North America Immunology Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Immunology Drug Revenue (2021-2032)
- 7.3.2 Europe Immunology Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Immunology Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Immunology Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Immunology Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Immunology Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Eisai Co.
- 8.1.1 Eisai Co. Company Information
- 8.1.2 Eisai Co. Business Overview
- 8.1.3 Eisai Co. Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Eisai Co. Immunology Drug Product Portfolio
- 8.1.5 Eisai Co. Recent Developments
- 8.2 Eli Lilly and Company
- 8.2.1 Eli Lilly and Company Company Information
- 8.2.2 Eli Lilly and Company Business Overview
- 8.2.3 Eli Lilly and Company Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Eli Lilly and Company Immunology Drug Product Portfolio
- 8.2.5 Eli Lilly and Company Recent Developments
- 8.3 Pfizer
- 8.3.1 Pfizer Company Information
- 8.3.2 Pfizer Business Overview
- 8.3.3 Pfizer Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Pfizer Immunology Drug Product Portfolio
- 8.3.5 Pfizer Recent Developments
- 8.4 GlaxoSmithKline plc
- 8.4.1 GlaxoSmithKline plc Company Information
- 8.4.2 GlaxoSmithKline plc Business Overview
- 8.4.3 GlaxoSmithKline plc Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 GlaxoSmithKline plc Immunology Drug Product Portfolio
- 8.4.5 GlaxoSmithKline plc Recent Developments
- 8.5 Bayer AG
- 8.5.1 Bayer AG Company Information
- 8.5.2 Bayer AG Business Overview
- 8.5.3 Bayer AG Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Bayer AG Immunology Drug Product Portfolio
- 8.5.5 Bayer AG Recent Developments
- 8.6 Seattle Genetics
- 8.6.1 Seattle Genetics Company Information
- 8.6.2 Seattle Genetics Business Overview
- 8.6.3 Seattle Genetics Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Seattle Genetics Immunology Drug Product Portfolio
- 8.6.5 Seattle Genetics Recent Developments
- 8.7 Sanofi Aventis LLC.
- 8.7.1 Sanofi Aventis LLC. Company Information
- 8.7.2 Sanofi Aventis LLC. Business Overview
- 8.7.3 Sanofi Aventis LLC. Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Sanofi Aventis LLC. Immunology Drug Product Portfolio
- 8.7.5 Sanofi Aventis LLC. Recent Developments
- 8.8 Genentech
- 8.8.1 Genentech Company Information
- 8.8.2 Genentech Business Overview
- 8.8.3 Genentech Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Genentech Immunology Drug Product Portfolio
- 8.8.5 Genentech Recent Developments
- 8.9 F. Hoffmann-La Roche Ltd.
- 8.9.1 F. Hoffmann-La Roche Ltd. Company Information
- 8.9.2 F. Hoffmann-La Roche Ltd. Business Overview
- 8.9.3 F. Hoffmann-La Roche Ltd. Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 F. Hoffmann-La Roche Ltd. Immunology Drug Product Portfolio
- 8.9.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 8.10 Autoimmune Inc.
- 8.10.1 Autoimmune Inc. Company Information
- 8.10.2 Autoimmune Inc. Business Overview
- 8.10.3 Autoimmune Inc. Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Autoimmune Inc. Immunology Drug Product Portfolio
- 8.10.5 Autoimmune Inc. Recent Developments
- 8.11 Active Biotech
- 8.11.1 Active Biotech Company Information
- 8.11.2 Active Biotech Business Overview
- 8.11.3 Active Biotech Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Active Biotech Immunology Drug Product Portfolio
- 8.11.5 Active Biotech Recent Developments
- 8.12 Abbott Laboratories
- 8.12.1 Abbott Laboratories Company Information
- 8.12.2 Abbott Laboratories Business Overview
- 8.12.3 Abbott Laboratories Immunology Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Abbott Laboratories Immunology Drug Product Portfolio
- 8.12.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Immunology Drug Value Chain Analysis
- 9.1.1 Immunology Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Immunology Drug Production Mode & Process
- 9.2 Immunology Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Immunology Drug Distributors
- 9.2.3 Immunology Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst